Pamela Wedel has more than twenty-five years of drug development experience in biotechnology, pharmaceutical, and CRO industries. This experience includes leadership of cross-functional project teams, direction of multinational clinical development programs and contribution to early-stage product development strategies. Her therapeutic experience spans multiple therapeutic areas, including gastroenterology, CNS, neuroscience, oncology, dermatology and cardiology. Before joining Amplyx, Pamela was Executive Director of Clinical Operations at Lumena Pharmaceuticals where she played a key role in the advancement of multiple global clinical trials in rare pediatric cholestatic liver disease. Following Shire Pharmaceutical’s acquisition of Lumena in June 2015, she stayed-on with the company and assumed the role of Site Head for Shire San Diego in June 2015. Additional prior experience most recently includes senior leadership positions at BrainCells, Inc, a biotech company developing therapeutics for CNS and neurological disorders, Therapeutics, Inc., a specialty CRO focused on development of dermatological products, PAREXEL, a global CRO, and Ancile Pharmaceuticals, a company dedicated to botanical research and drug development. Pamela holds a BS in Biology from San Diego State University.